阿尔茨海默氏症粉样β-的水-4介导聚合
1Computational Biology Division, DRDO Center for Life Science, Bharathiar University Campus, Coimbatore 641046, Tamil Nadu, India.
ACS chemical neuroscience
|July 24, 2023
概括
水-4 (AQP4) 蛋白相互作用减缓了阿尔茨海默氏症的细胞表面的粉样聚合. 这种相互作用降低了的毒性,并有助于脑细胞的清除,提供了新的治疗见解.
科学领域:
- 神经科学是一个神经科学.
- 生物物理学的生物物理.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病的特点是粉样聚合,导致神经毒性和痴呆.
- 从脑细胞,特别是星球细胞中清除这些有毒的粉样蛋白寡合体,对于预防神经元损伤至关重要.
- 水-4 (AQP4) 涉及阿尔茨海默氏症病因学,其在清除中的作用是研究的关键领域.
研究的目的:
- 为了研究阿尔茨海默氏症粉样在脂质表面的聚合.
- 阐明水素-4 (AQP4) 在促进粉样从星球细胞清除中的作用.
- 了解AQP4影响粉样蛋白聚合和毒性的分子机制.
主要方法:
- 用全原子和粗粒度分子动力学 (MD) 模拟来建模粉样蛋白聚合在脂质双层.
- 文本挖掘被用来分析蛋白质-蛋白质相互作用网络,并确定AQP4表达和粉样蛋白聚合之间的相关性.
- 在试验室中使用硫黄素光谱法来测量在存在AQP4的情况下的聚率.
主要成果:
- 分子动力学模拟显示,AQP4与脂质双层表面的粉样分子聚合物相互作用,减缓它们的聚合.
- 这种相互作用保留了的螺旋结构,降低了它的疏水性,降低了对脂质表面的毒性.
- 长期模拟证实了AQP4对聚合的抑制作用,并揭示了aquaporin水动态的干扰,这可能解释了阿尔茨海默病中大脑水流的改变.
- 在体外实验表明,当AQP4存在时,聚率显著下降.
结论:
- 水-4通过与阿尔茨海默氏症的粉样在天体细胞膜上相互作用并抑制其聚合而起保护作用.
- 以AQP4为媒介的降低毒性和增强的清除机制为阿尔茨海默病提供了潜在的治疗策略.
- 该研究提供了关于AQP4功能,大脑水平衡和阿尔茨海默病的病理生理学之间的联系的见解.
相关概念视频
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:25Aquaporins
4.9K
Aquaporins or AQPs are a family of integral membrane proteins whose primary function is to transport water, while some called aquaglyceroporins also transport glycerol. In addition, aquaporins have also been suspected to be involved in transporting volatile substances, such as carbon dioxide and ammonia, across membranes. Such AQPs that act as gas channels are often highly expressed in cells involved in the gaseous exchange, such as red blood cells, epithelial cells, and pulmonary capillaries.
4.9K
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:26Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524